Furet Pascal, Bold Guido, Meyer Thomas, Roesel Johannes, Guagnano Vito
Novartis Pharma AG, Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland.
J Med Chem. 2006 Jul 27;49(15):4451-4. doi: 10.1021/jm060368s.
FLT3 kinase inhibitors are currently under investigation as a new treatment for acute myeloid leukemia. We report here a molecular concept invoking interactions between an aromatic ring and the side chains of Phe691 and Cys828, two residues of the ATP pocket, to obtain potent and specific inhibitors of this kinase. The hypothesis has been validated by the successful design of a new inhibitor prototype showing promising antiproliferative activity in cellular assays.
FLT3激酶抑制剂目前正作为急性髓系白血病的一种新疗法进行研究。我们在此报告一种分子概念,即通过一个芳香环与ATP口袋中的两个残基(Phe691和Cys828)的侧链之间的相互作用,来获得该激酶的强效且特异性抑制剂。这一假设已通过成功设计一种新的抑制剂原型得到验证,该原型在细胞试验中显示出有前景的抗增殖活性。